{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.99","value":"0.6"},{"groupId":"OG001","spread":"8.50","value":"0.9"}]}],"title":"Week 1, n=231, 440"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.31","value":"1.1"},{"groupId":"OG001","spread":"9.16","value":"2.3"}]}],"title":"Week 2, n=227, 435"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.83","value":"1.7"},{"groupId":"OG001","spread":"9.01","value":"2.7"}]}],"title":"Week 4, n=217, 428"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.74","value":"2.3"},{"groupId":"OG001","spread":"8.88","value":"2.9"}]}],"title":"Week 6, n=195, 419"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.27","value":"2.3"},{"groupId":"OG001","spread":"9.98","value":"3.6"}]}],"title":"Week 8, n=190, 414"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.30","value":"3.8"},{"groupId":"OG001","spread":"9.93","value":"4.1"}]}],"title":"Week 12, n=164, 404"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.81","value":"4.7"},{"groupId":"OG001","spread":"9.87","value":"4.2"}]}],"title":"Week 16, n=140, 375"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.05","value":"3.4"},{"groupId":"OG001","spread":"9.73","value":"4.8"}]}],"title":"Week 20, n=135, 363"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.34","value":"4.8"},{"groupId":"OG001","spread":"10.91","value":"4.7"}]}],"title":"Week 24, n=88, 248"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.29","value":"4.6"},{"groupId":"OG001","spread":"9.75","value":"4.5"}]}],"title":"Week 28, n=73, 200"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.48","value":"6.1"},{"groupId":"OG001","spread":"10.46","value":"5.5"}]}],"title":"Week 32, n=68, 182"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.55","value":"5.5"},{"groupId":"OG001","spread":"11.84","value":"4.1"}]}],"title":"Week 36, n=68, 174"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.33","value":"5.8"},{"groupId":"OG001","spread":"10.32","value":"5.0"}]}],"title":"Week 40, n=64, 166"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.30","value":"5.3"},{"groupId":"OG001","spread":"9.94","value":"5.5"}]}],"title":"Week 44, n=64, 166"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.54","value":"2.9"},{"groupId":"OG001","spread":"10.84","value":"4.3"}]}],"title":"End of Treatment, n=212, 419"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.47","value":"2.7"},{"groupId":"OG001","spread":"10.38","value":"3.5"}]}],"title":"4-week FU, n=204, 397"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.23","value":"0.5"},{"groupId":"OG001","spread":"10.40","value":"1.7"}]}],"title":"12-week FU, n=197, 400"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.61","value":"0.1"},{"groupId":"OG001","spread":"10.34","value":"0.5"}]}],"title":"24-week FU, n=197, 393"}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"description":"Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)","title":"Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"beats per minute"}